rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2022-397-412rsp-3192Research ArticleПЕРЕДОВАЯLEADING ARTICLEСистемная красная волчанка: история и современностьSystemic lupus erythematosus: history and modernityhttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а;

119991, Москва, ул. Трубецкая, 8, стр. 2

119991, Moscow, Trubetskaya str., 8, building 2

nasonov@irramn.ruhttps://orcid.org/0000-0002-5206-1732СоловьевС. К.SolovievS. K.

115522, Москва, Каширское шоссе, 34а

https://orcid.org/0000-0002-0297-8163АршиновА. В.ArshinovA. V.

150000, Ярославль, ул. Революционная, 5

150000, Yaroslavl, Revolyutsionnaya str., 5

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of Rheumatology V.A. Nasonova Research Institute of RheumatologyRussian FederationФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииРоссияYaroslavl State Medical UniversityRussian Federation202206092022604397412Copyright © Насонов Е.Л., Соловьев С.К., Аршинов А.В., 20222022Насонов Е.Л., Соловьев С.К., Аршинов А.В.Nasonov E.L., Soloviev S.K., Arshinov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3192

Системная красная волчанка (СКВ) – системное аутоиммунное ревматическое заболевание неизвестной этиологии, характеризующееся гиперпродукцией органонеспецифических аутоантител к различным компонентам клеточного ядра и развитием иммуновоспалительного повреждения внутренних органов. В настоящее время СКВ рассматривается как прототип системной аутоиммунной патологии человека, центральным механизмом иммунопатогенеза которой является нарушение иммунологической толерантности к собственным аутоантигенам, обусловленное сложным взаимодействием генетических, эпигенетических, внешнесредовых факторов. В статье обсуждаются история учения о СКВ, вклад российских ученых (В.А. Насоновой и других) в изучение этой проблемы, современные направления клинических и научных исследований, связанные с совершенствованием критериев диагностики и фармакотерапии этого заболевания. 

Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by hyperproduction of non-organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. Currently, SLE is considered as a prototype of a systemic human autoimmune pathology, the central mechanism of immunopathogenesis of which is a violation of immunological tolerance to self-antigens, due to a complex interaction of genetic, epigenetic, environmental factors. The publication discusses the history of the study of SLE, the contribution of Russian scientists (V.A. Nasonova and others) to the study of th is problem, current trends in clinical and scientific research related to the improvement of diagnostic criteria and pharmacotherapy of this disease. 

системная красная волчанкигенно-инженерные биологические препаратыцитокиныВ-клеткиsystemic lupus erythematosusgenetically engineered biological agentscytokinesB cellsReferencesTsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-2121. doi: 10.1056/NEJMra1100359Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-2121. doi: 10.1056/NEJMra1100359Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39Norman RA. The History of lupus erythematosus and discoid lupus: From Hippocrates to the present. Lupus Open Access. 2016;1(1):102.Norman RA. The History of lupus erythematosus and discoid lupus: From Hippocrates to the present. Lupus Open Access. 2016;1(1):102.Kaposi M. Neue Beiträge zur Kenntniss des Lupus erythematosus. Arch Derm Syphilol. 1872;4:36-78.Kaposi M. Neue Beiträge zur Kenntniss des Lupus erythematosus. Arch Derm Syphilol. 1872;4:36-78.Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med Sci. 1895;110:629-646.Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med Sci. 1895;110:629-646.Sequeira JH, Balean H. Lupus erythematosus: A clinical study of seventy-one cases. Br J Dermatol. 1902;14:367-379.Sequeira JH, Balean H. Lupus erythematosus: A clinical study of seventy-one cases. Br J Dermatol. 1902;14:367-379.Libman E, Sachs B. A hitherto undescribed form of valvular and mural endocarditis. Arch Inter Med. 1924;33:701-737.Libman E, Sachs B. A hitherto undescribed form of valvular and mural endocarditis. Arch Inter Med. 1924;33:701-737.Baehr G, Klemperer P, Chifrin A. Diffuse disease of the peripheral circulation usually associated with lupus erythematosus and endocarditis. Trans Assoc Am Phis. 1935;50:139-155.Baehr G, Klemperer P, Chifrin A. Diffuse disease of the peripheral circulation usually associated with lupus erythematosus and endocarditis. Trans Assoc Am Phis. 1935;50:139-155.Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements; “tart” cell and “L.E.” cell. Proc Staff Meet Mayo Clin. 1948 Jan 21;23:25-28.Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements; “tart” cell and “L.E.” cell. Proc Staff Meet Mayo Clin. 1948 Jan 21;23:25-28.Haserick JR, Long R. Systemic lupus erythematosus preceded by false-positive test for syphilis: Presentations five cases. Ann Intern Med. 1952;37:559-565.Haserick JR, Long R. Systemic lupus erythematosus preceded by false-positive test for syphilis: Presentations five cases. Ann Intern Med. 1952;37:559-565.Насонова ВА. Системная красная волчанка. М.:Медицина;1972. [Nasonova VA. Systemic lupus erythematosus. Moscow:Meditsina; 1972 (In Russ.)].Nasonova VA. Systemic lupus erythematosus. Moscow:Meditsina; 1972 (In Russ.).Тареев ЕМ, Виноградова ОМ, Насонова ВА, Гусева НГ. Коллагенозы. М.;1965.Tareev EM, Vinogradova OM, Nasonova VA, Guseva NG. Collagenoses. Moscow;1965 (In Russ.).Page F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951;2:755-758. 14. Wallace DJ. The history of antimalarials. Lupus. 1996;5(Suppl 1): S2-S3.Page F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951;2:755-758. 14. Wallace DJ. The history of antimalarials. Lupus. 1996;5(Suppl 1): S2-S3.Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: Overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001. doi: 10.1177/1759720X211073001Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: Overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001. doi: 10.1177/1759720X211073001Almeida-Brasil CC, Hanly JG, Urowitz M, Clarke AE, RuizIrastorza G, Gordon C, et al. Flares after hydroxychloroquine reduction or discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022;81(3):370-378. doi: 10.1136/annrheumdis-2021-221295Almeida-Brasil CC, Hanly JG, Urowitz M, Clarke AE, RuizIrastorza G, Gordon C, et al. Flares after hydroxychloroquine reduction or discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022;81(3):370-378. doi: 10.1136/annrheumdis-2021-221295Hench PS, Kendall EC. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949;24:181-197.Hench PS, Kendall EC. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949;24:181-197.Hench PS. The reversibility of certain rheumatic and nonrheumatic conditions by the use of cortisone or of the pituitary adrenocotropic hormone. Ann Intern Med. 1952;36:1-38.Hench PS. The reversibility of certain rheumatic and nonrheumatic conditions by the use of cortisone or of the pituitary adrenocotropic hormone. Ann Intern Med. 1952;36:1-38.Ruiz-Irastorza G, Ugarte A, Ruiz-Arruza I, Khamashta M. Seventy years after Hench’s Nobel prize: Revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus. 2020;29(10):1155- 1167. doi: 10.1177/0961203320930099Ruiz-Irastorza G, Ugarte A, Ruiz-Arruza I, Khamashta M. Seventy years after Hench’s Nobel prize: Revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus. 2020;29(10):1155- 1167. doi: 10.1177/0961203320930099Cathcart ES, Idelson BA, Scheinberg MA, Couser WG. Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis. Lancet. 1976;i:163-166. 21. Scheinberg M. The history of pulse therapy in lupus nephritis (1976–2016). Lupus Science Medicine. 2016;3:e000149. doi: 10.1136/lupus-2016-000149Cathcart ES, Idelson BA, Scheinberg MA, Couser WG. Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis. Lancet. 1976;i:163-166. 21. Scheinberg M. The history of pulse therapy in lupus nephritis (1976–2016). Lupus Science Medicine. 2016;3:e000149. doi: 10.1136/lupus-2016-000149Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9(9):2709. doi: 10.3390/jcm9092709Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9(9):2709. doi: 10.3390/jcm9092709Ugarte-Gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Reátegui-Sokolova C, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: A systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. 2021;8(1):e000590. doi: 10.1136/lupus-2021-000590Ugarte-Gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Reátegui-Sokolova C, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: A systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. 2021;8(1):e000590. doi: 10.1136/lupus-2021-000590Osborne ED, Jordon JW, Hoak FC, Pschierer FJ. Nitrogen mustard therapy in cutaneous blastomatous disease. JAMA. 1947;135: 1123-1128.Osborne ED, Jordon JW, Hoak FC, Pschierer FJ. Nitrogen mustard therapy in cutaneous blastomatous disease. JAMA. 1947;135: 1123-1128.Alekberova ZS, Parfanovich MI, Nasonova VA, Zhdanov VM. Molecular pathogenesis of systemic lupus erythematosus. Arch Virol. 1975;47(2):109-121. doi: 10.1007/BF01320551Alekberova ZS, Parfanovich MI, Nasonova VA, Zhdanov VM. Molecular pathogenesis of systemic lupus erythematosus. Arch Virol. 1975;47(2):109-121. doi: 10.1007/BF01320551Iwata S, Tanaka Y. Association of viral infection with the development and pathogenesis of systemic lupus erythematosus. Front Med (Lausanne). 2022;9:849120. doi: 10.3389/fmed.2022.849120Iwata S, Tanaka Y. Association of viral infection with the development and pathogenesis of systemic lupus erythematosus. Front Med (Lausanne). 2022;9:849120. doi: 10.3389/fmed.2022.849120Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605-614. doi: 10.1038/s41590-020-0677-6Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605-614. doi: 10.1038/s41590-020-0677-6Gupta S, Kaplan MJ. Bite of the wolf: innate immune responses propagate autoimmunity in lupus. J Clin Invest. 2021;131(3): e144918. doi: 10.1172/JCI144918Gupta S, Kaplan MJ. Bite of the wolf: innate immune responses propagate autoimmunity in lupus. J Clin Invest. 2021;131(3): e144918. doi: 10.1172/JCI144918Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020;16(10):565-579. doi: 10.1038/s41584-020-0480-7Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020;16(10):565-579. doi: 10.1038/s41584-020-0480-7Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151- 1159. doi: 10.1136/annrheumdis-2018-214819Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151- 1159. doi: 10.1136/annrheumdis-2018-214819Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):v4-v11. doi: 10.1093/rheumatology/keaa379Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):v4-v11. doi: 10.1093/rheumatology/keaa379Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, et al. Performance of the 2019 EULAR/ ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Ann Rheum Dis. 2020;79(10):1333-1339. doi: 10.1136/annrheumdis-2020-217162Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, et al. Performance of the 2019 EULAR/ ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Ann Rheum Dis. 2020;79(10):1333-1339. doi: 10.1136/annrheumdis-2020-217162Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, et al.; Systemic Lupus Erythematosus Classification Criteria Steering Committee. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: A systematic literature review and meta-regression of diagnostic data. Arthritis Care Res (Hoboken). 2018;70(3):428-438. doi: 10.1002/acr.23292Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, et al.; Systemic Lupus Erythematosus Classification Criteria Steering Committee. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: A systematic literature review and meta-regression of diagnostic data. Arthritis Care Res (Hoboken). 2018;70(3):428-438. doi: 10.1002/acr.23292Pisetsky DS, Bossuyt X, Meroni PL. ANA as an entry criterion for the classification of SLE. Autoimmun Rev. 2019:102400. doi: 10.1016/j.autrev.2019.102400Pisetsky DS, Bossuyt X, Meroni PL. ANA as an entry criterion for the classification of SLE. Autoimmun Rev. 2019:102400. doi: 10.1016/j.autrev.2019.102400Aringer M, Costenbader K, Dörner T, Johnson SR. Advances in SLE classification criteria. J Autoimmun. 2022:102845. doi: 10.1016/j.jaut.2022.102845Aringer M, Costenbader K, Dörner T, Johnson SR. Advances in SLE classification criteria. J Autoimmun. 2022:102845. doi: 10.1016/j.jaut.2022.102845Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, PonsEstel G, et al. Differentiating between UCTD and early-stage SLE: From definitions to clinical approach. Nat Rev Rheumatol. 2022;18(1):9-21. doi: 10.1038/s41584-021-00710-2Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, PonsEstel G, et al. Differentiating between UCTD and early-stage SLE: From definitions to clinical approach. Nat Rev Rheumatol. 2022;18(1):9-21. doi: 10.1038/s41584-021-00710-2Насонов ЕЛ, Попкова ТВ, Панафидина ТА. Проблемы ранней системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-128. doi: 10.47360/1995-4484-2021-119-128Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID19 pandemic. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):119-128 (In Russ.). doi: 10.47360/1995-4484-2021-119-128Choi MY, Costenbader KH. Understanding the concept of preclinical autoimmunity: Prediction and prevention of systemic lupus erythematosus: Identifying risk factors and developing strategies against disease development. Front Immunol. 2022;13:890522. doi: 10.3389/fimmu.2022.890522Choi MY, Costenbader KH. Understanding the concept of preclinical autoimmunity: Prediction and prevention of systemic lupus erythematosus: Identifying risk factors and developing strategies against disease development. Front Immunol. 2022;13:890522. doi: 10.3389/fimmu.2022.890522Aringer M, Alarcón-Riquelme ME, Clowse M, Pons-Estel GJ, Vital EM, Dall’Era M. A glimpse into the future of systemic lupus erythematosus. Ther Adv Musculoskelet Dis. 2022;14:1759720X221086719. doi: 10.1177/1759720X221086719Aringer M, Alarcón-Riquelme ME, Clowse M, Pons-Estel GJ, Vital EM, Dall’Era M. A glimpse into the future of systemic lupus erythematosus. Ther Adv Musculoskelet Dis. 2022;14:1759720X221086719. doi: 10.1177/1759720X221086719Barturen G, Babaei S, Català-Moll F, Martínez-Bueno M, Makowska Z, Martorell-Marugán J, et al. Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. Arthritis Rheumatol. 2021;73(6):1073-1085. doi: 10.1002/art.41610Barturen G, Babaei S, Català-Moll F, Martínez-Bueno M, Makowska Z, Martorell-Marugán J, et al. Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. Arthritis Rheumatol. 2021;73(6):1073-1085. doi: 10.1002/art.41610Sandling JK, Pucholt P, Hultin Rosenberg L, Farias FHG, Kozyrev SV, Eloranta ML, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021;80(1):109-117. doi: 10.1136/annrheumdis-2020-218636Sandling JK, Pucholt P, Hultin Rosenberg L, Farias FHG, Kozyrev SV, Eloranta ML, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021;80(1):109-117. doi: 10.1136/annrheumdis-2020-218636Omarjee O, Picard C, Frachette C, Moreews M, Rieux-Laucat F, Soulas-Sprauel P, et al. Monogenic lupus: Dissecting heterogeneity. Autoimmun Rev. 2019;18(10):102361. doi: 10.1016/j.autrev.2019.102361Omarjee O, Picard C, Frachette C, Moreews M, Rieux-Laucat F, Soulas-Sprauel P, et al. Monogenic lupus: Dissecting heterogeneity. Autoimmun Rev. 2019;18(10):102361. doi: 10.1016/j.autrev.2019.102361van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. doi: 10.1136/annrheumdis-2013-205139Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: Advancing towards its implementation. Nat Rev Rheumatol. 2022;18(3):146-157. doi: 10.1038/s41584-021-00739-3Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: Advancing towards its implementation. Nat Rev Rheumatol. 2022;18(3):146-157. doi: 10.1038/s41584-021-00739-3Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol. 2019;15(1):30-48. doi: 10.1038/s41584-018-0133-2Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol. 2019;15(1):30-48. doi: 10.1038/s41584-018-0133-2Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-2358. doi: 10.1016/S0140-6736(19)30546-XDörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-2358. doi: 10.1016/S0140-6736(19)30546-XUgarte-Gil MF, Mendoza-Pinto C, Reátegui-Sokolova C, PonsEstel GJ, van Vollenhoven RF, Bertsias G, et al. Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: A systematic literature review. Lupus Sci Med. 2021;8(1):e000542. doi: 10.1136/lupus2021-000542Ugarte-Gil MF, Mendoza-Pinto C, Reátegui-Sokolova C, PonsEstel GJ, van Vollenhoven RF, Bertsias G, et al. Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: A systematic literature review. Lupus Sci Med. 2021;8(1):e000542. doi: 10.1136/lupus2021-000542Соловьев СК, Асеева ЕА, Зоткин ЕГ, Шкиреева СЮ, Насонов ЕЛ. Проблемы низкой активности и ремиссии при системной красной волчанке. Научно-практическая ревматология. 2019;57(2):218-221. doi: 10.14412/1995-4484-2019-218-221Soloviev SK, Aseeva EA, Zotkin EG, Kireeva SYu, Nasonov EL. Problems of low activity and remission in systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(2):218- 221 (In Russ.). doi: 10.14412/1995-4484-2019-218-221Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D’Cruz D, et al.; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018;57(1):e1- e45. doi: 10.1093/rheumatology/kex286Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D’Cruz D, et al.; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018;57(1):e1- e45. doi: 10.1093/rheumatology/kex286Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, et al.; Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus) Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77(11):1549-1557. doi: 10.1136/annrheumdis-2018-213512Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, et al.; Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus) Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77(11):1549-1557. doi: 10.1136/annrheumdis-2018-213512Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. doi: 10.1136/annrheumdis2020-216924Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. doi: 10.1136/annrheumdis2020-216924Решетняк ТМ, Нурбаева КС. Прямые оральные антикоагулянты при антифосфолипидном синдроме. Научно-практическая ревматология. 2020;58(6):708-715. doi: 10.47360/1995-4484-2020-708-715Reshetnyak TM, Nurbaeva KS. Direct-acting oral anticoagulants in antiphospholipid syndrome. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(6):708-715 (In Russ.). doi: 10.47360/1995-4484-2020-708-715Yavne Y, Edel Y, Berman J, Eviatar T, Shepshelovich D. Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus. Rheumatology (Oxford). 2021;61(1):240-248. doi: 10.1093/rheumatology/keab306Yavne Y, Edel Y, Berman J, Eviatar T, Shepshelovich D. Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus. Rheumatology (Oxford). 2021;61(1):240-248. doi: 10.1093/rheumatology/keab306Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14. doi: 10.14412/1995-4484-2020-5-14Solovyev SK, Aseeva EA, Popkova TV, Lila AM, Mazurov VI, Nasonov EL. Systemic lupus erythematosus: New horizons for diagnosis and therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(1):5-14 (In Russ.). doi: 10.14412/1995-4484-2020-5-14Kandane-Rathnayake R, Louthrenoo W, Hoi A, Luo SF, Wu YJ, Chen YH, et al.; Asia-Pacific Lupus Collaboration. ‘Not at target’: Prevalence and consequences of inadequate disease control in systemic lupus erythematosus – a multinational observational cohort study. Arthritis Res Ther. 2022;24(1):70. doi: 10.1186/s13075-022-02756-3Kandane-Rathnayake R, Louthrenoo W, Hoi A, Luo SF, Wu YJ, Chen YH, et al.; Asia-Pacific Lupus Collaboration. ‘Not at target’: Prevalence and consequences of inadequate disease control in systemic lupus erythematosus – a multinational observational cohort study. Arthritis Res Ther. 2022;24(1):70. doi: 10.1186/s13075-022-02756-3Bultink IEM, de Vries F, van Vollenhoven RF, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford). 2021;60(1):207-216. doi: 10.1093/rheumatology/keaa267Bultink IEM, de Vries F, van Vollenhoven RF, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford). 2021;60(1):207-216. doi: 10.1093/rheumatology/keaa267Singh RR, Yen EY. SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus. 2018;27(10): 1577-1581. doi: 10.1177/0961203318786436Singh RR, Yen EY. SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus. 2018;27(10): 1577-1581. doi: 10.1177/0961203318786436Shin JI, Li H, Park S, Yang JW, Lee KH, Jo Y, et al. Induction and maintenance treatment of lupus nephritis: A comprehensive review of meta-analyses. J Clin Med. 2022;11(2):343. doi: 10.3390/jcm11020343Shin JI, Li H, Park S, Yang JW, Lee KH, Jo Y, et al. Induction and maintenance treatment of lupus nephritis: A comprehensive review of meta-analyses. J Clin Med. 2022;11(2):343. doi: 10.3390/jcm11020343Mok CC. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):429-438. doi: 10.1016/j.berh.2017.09.010Mok CC. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):429-438. doi: 10.1016/j.berh.2017.09.010Dall’Era M. Treatment of lupus nephritis: Current paradigms and emerging strategies. Curr Opin Rheumatol. 2017;29(3):241-247. doi: 10.1097/BOR.0000000000000381Dall’Era M. Treatment of lupus nephritis: Current paradigms and emerging strategies. Curr Opin Rheumatol. 2017;29(3):241-247. doi: 10.1097/BOR.0000000000000381Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al.; AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019; 95(1):219-231. doi: 10.1016/j.kint.2018.08.025Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al.; AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019; 95(1):219-231. doi: 10.1016/j.kint.2018.08.025Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-XRovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-XArriens C, Polyakova S, Adzerikho I, Randhawa S, Solomons N. OP0277 AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN). Ann Rheum Dis. 2020;79:172.2-172.3. doi: 10.1136/annrheumdis2020-eular.5010Arriens C, Polyakova S, Adzerikho I, Randhawa S, Solomons N. OP0277 AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN). Ann Rheum Dis. 2020;79:172.2-172.3. doi: 10.1136/annrheumdis2020-eular.5010Sin FE, Isenberg D. An evaluation of voclosporin for the treatment of lupus nephritis. Expert Opin Pharmacother. 2018;19(14):1613- 1621. doi: 10.1080/14656566.2018.1516751Sin FE, Isenberg D. An evaluation of voclosporin for the treatment of lupus nephritis. Expert Opin Pharmacother. 2018;19(14):1613- 1621. doi: 10.1080/14656566.2018.1516751Насонов ЕЛ, Соловьев СК. Перспективы фармакотерапии системной красной волчанки. Научно-практическая ревматология. 2014;52(3):311-321. doi: 10.14412/1995-4484-2014-311-321Nasonov EL, Solovyev SK. Prospects for pharmacotherapy of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(3):311-321 (In Russ.). doi: 10.14412/1995-4484-2014-311-321Yavuz S, Lipsky PE. Current status of the evaluation and management of lupus patients and future prospects. Front Med (Lausanne). 2021;8:682544. doi: 10.3389/fmed.2021.682544Yavuz S, Lipsky PE. Current status of the evaluation and management of lupus patients and future prospects. Front Med (Lausanne). 2021;8:682544. doi: 10.3389/fmed.2021.682544Allen ME, Rus V, Szeto GL. Leveraging heterogeneity in systemic lupus erythematosus for new therapies. Trends Mol Med. 2021; 27(2):152-171. doi: 10.1016/j.molmed.2020.09.009Allen ME, Rus V, Szeto GL. Leveraging heterogeneity in systemic lupus erythematosus for new therapies. Trends Mol Med. 2021; 27(2):152-171. doi: 10.1016/j.molmed.2020.09.009Idborg H, Oke V. Cytokines as biomarkers in systemic lupus erythematosus: Value for diagnosis and drug therapy. Int J Mol Sci. 2021;22(21):11327. doi: 10.3390/ijms222111327Idborg H, Oke V. Cytokines as biomarkers in systemic lupus erythematosus: Value for diagnosis and drug therapy. Int J Mol Sci. 2021;22(21):11327. doi: 10.3390/ijms222111327Arora S, Rovin BH. Expert perspective: An approach to refractory lupus nephritis. Arthritis Rheumatol. 2022;74(6):915-926. doi: 10.1002/art.42092Arora S, Rovin BH. Expert perspective: An approach to refractory lupus nephritis. Arthritis Rheumatol. 2022;74(6):915-926. doi: 10.1002/art.42092Zucchi D, Elefante E, Schilirò D, Signorini V, Trentin F, Bortoluzzi A, et al. One year in review 2022: Systemic lupus erythematosus. Clin Exp Rheumatol. 2022;40(1):4-14. doi: 10.55563/clinexprheumatol/nolysyZucchi D, Elefante E, Schilirò D, Signorini V, Trentin F, Bortoluzzi A, et al. One year in review 2022: Systemic lupus erythematosus. Clin Exp Rheumatol. 2022;40(1):4-14. doi: 10.55563/clinexprheumatol/nolysyRuiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: New drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(Suppl 5):v69-v81. doi: 10.1093/rheumatology/keaa403Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: New drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(Suppl 5):v69-v81. doi: 10.1093/rheumatology/keaa403Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to- severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-233. doi: 10.1002/art.27233Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to- severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-233. doi: 10.1002/art.27233Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al.; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-1226. doi: 10.1002/art.34359Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al.; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-1226. doi: 10.1002/art.34359Rydén-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med. 2016;3(1): e000163. doi: 10.1136/lupus-2016-000163Rydén-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med. 2016;3(1): e000163. doi: 10.1136/lupus-2016-000163Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. doi: 10.14412/1995-4484-2019-3-40Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.). doi: 10.14412/1995-4484-2019-3-40Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebocontrolled trial. Ann Rheum Dis. 2022;81(1):100-107. doi: 10.1136/annrheumdis-2021-220920Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebocontrolled trial. Ann Rheum Dis. 2022;81(1):100-107. doi: 10.1136/annrheumdis-2021-220920Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368-2379. doi: 10.1002/art.38037Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368-2379. doi: 10.1002/art.38037Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, et al.; EMBODY Investigator Group. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017;69(2):362-375. doi: 10.1002/art.39856Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, et al.; EMBODY Investigator Group. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017;69(2):362-375. doi: 10.1002/art.39856Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, et al.; ADDRESS II Investigators. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: Results of a twentyfour-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018;70(2):266-276. doi: 10.1002/art.40360Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, et al.; ADDRESS II Investigators. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: Results of a twentyfour-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018;70(2):266-276. doi: 10.1002/art.40360Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33. doi: 10.1186/ar3738Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33. doi: 10.1186/ar3738Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75(2):332-340. doi: 10.1136/annrheumdis-2015-207654Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75(2):332-340. doi: 10.1136/annrheumdis-2015-207654Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): Results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(6):883-889. doi: 10.1136/annrheumdis-2018-213032Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): Results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(6):883-889. doi: 10.1136/annrheumdis-2018-213032US National library of Medicine. ClinicalTrials.gov URL: https://ClinicalTrials.gov/show/NCT02885610)US National library of Medicine. ClinicalTrials.gov URL: https://ClinicalTrials.gov/show/NCT02885610)US National library of Medicine. ClinicalTrials.gov URL: https://ClinicalTrials.gov/show/NCT04082416)US National library of Medicine. ClinicalTrials.gov URL: https://ClinicalTrials.gov/show/NCT04082416)Furie R, Morand EF, Bruce IN, Manzi S, Kalunian K, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208-e219.Furie R, Morand EF, Bruce IN, Manzi S, Kalunian K, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208-e219.Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020; 382(3):211-221. doi: 10.1056/NEJMoa1912196Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020; 382(3):211-221. doi: 10.1056/NEJMoa1912196Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study. Arthritis Rheumatol. 2021;73(5):816- 825. doi: 10.1002/art.41598Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: Results of a phase II open-label extension study. Arthritis Rheumatol. 2021;73(5):816- 825. doi: 10.1002/art.41598Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496-506. doi: 10.1136/annrheumdis-2021-221478Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496-506. doi: 10.1136/annrheumdis-2021-221478Насонов ЕЛ, Авдеева АС, Попкова ТВ. Новые возможности фармакотерапии системной красной волчанки: перспективы применения анифролумаба (моноклональные антитела к рецепторам интерферона типа I). Научно-практическая ревматология. 2021;59(5):537-546. doi: 10.47360/1995-4484-2021-537-546Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(5):537- 546 (In Russ.). doi: 10.47360/1995-4484-2021-537-546Houssiau FA, Thanou A, Mazur M, Ramiterre E, Gomez Mora DA, Misterska-Skora M, et al. IFN-α kinoid in systemic lupus erythematosus: Results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis. 2020;79(3):347-355. doi: 10.1136/annrheumdis-2019-216379Houssiau FA, Thanou A, Mazur M, Ramiterre E, Gomez Mora DA, Misterska-Skora M, et al. IFN-α kinoid in systemic lupus erythematosus: Results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis. 2020;79(3):347-355. doi: 10.1136/annrheumdis-2019-216379Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(10):3077-3087. doi: 10.1002/art.27601Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(10):3077-3087. doi: 10.1002/art.27601Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379-389. doi: 10.1002/art.38260Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379-389. doi: 10.1002/art.38260Pimentel-Quiroz VR, Ugarte-Gil MF, Alarcón GS. Abatacept for the treatment of systemic lupus erythematosus. Expert Opin Investig Drugs. 2016;25(4):493-499. doi: 10.1517/13543784.2016.1154943Pimentel-Quiroz VR, Ugarte-Gil MF, Alarcón GS. Abatacept for the treatment of systemic lupus erythematosus. Expert Opin Investig Drugs. 2016;25(4):493-499. doi: 10.1517/13543784.2016.1154943Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(11):5397- 5407. doi: 10.1093/rheumatology/keab381Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(11):5397- 5407. doi: 10.1093/rheumatology/keab381Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168-1178. doi: 10.1002/art.24699Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168-1178. doi: 10.1002/art.24699Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al.; BLISS-76 Study Group. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-3930. doi: 10.1002/art.30613Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al.; BLISS-76 Study Group. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-3930. doi: 10.1002/art.30613Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. doi: 10.1016/S0140-6736(10)61354-2Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. doi: 10.1016/S0140-6736(10)61354-2Sheikh SZ, Scheinberg MA, Cheng-Chung Wei J, Tegzova D, Stohl W, Acayaba de Toledo R, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): A multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol. 2021:e122-e130. doi: 10.1016/S2665-9913(20)30355-6Sheikh SZ, Scheinberg MA, Cheng-Chung Wei J, Tegzova D, Stohl W, Acayaba de Toledo R, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): A multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol. 2021:e122-e130. doi: 10.1016/S2665-9913(20)30355-6Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-1838. doi: 10.1136/annrheumdis-2011-200831Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-1838. doi: 10.1136/annrheumdis-2011-200831Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403-413. doi: 10.1016/j.kint.2021.08.027Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403-413. doi: 10.1016/j.kint.2021.08.027Shrestha S, Budhathoki P, Adhikari Y, Marasini A, Bhandari S, Mir WAY, et al. Belimumab in lupus nephritis: A systematic review and meta-analysis. Cureus. 2021;13(12):e20440. doi: 10.7759/cureus.20440Shrestha S, Budhathoki P, Adhikari Y, Marasini A, Bhandari S, Mir WAY, et al. Belimumab in lupus nephritis: A systematic review and meta-analysis. Cureus. 2021;13(12):e20440. doi: 10.7759/cureus.20440Plüß M, Piantoni S, Tampe B, Kim AHJ, Korsten P. Belimumab for systemic lupus erythematosus – Focus on lupus nephritis. Hum Vaccin Immunother. 2022:2072143. doi: 10.1080/21645515.20 22.2072143Plüß M, Piantoni S, Tampe B, Kim AHJ, Korsten P. Belimumab for systemic lupus erythematosus – Focus on lupus nephritis. Hum Vaccin Immunother. 2022:2072143. doi: 10.1080/21645515.20 22.2072143Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol. 2016;68(9):2174-2183. doi: 10.1002/art.39722Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol. 2016;68(9):2174-2183. doi: 10.1002/art.39722Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542-552. doi: 10.1002/art.27221Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542-552. doi: 10.1002/art.27221Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: A phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017;76(3):534-542. doi: 10.1136/annrheumdis-2016-209668Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: A phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017;76(3):534-542. doi: 10.1136/annrheumdis-2016-209668van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: Results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155): 1330-1339. doi: 10.1016/S0140-6736(18)32167-6van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: Results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155): 1330-1339. doi: 10.1016/S0140-6736(18)32167-6van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Fei K, Gordon RM, et al. Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 2020;72(5):761-768. doi: 10.1002/art.41179van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Fei K, Gordon RM, et al. Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 2020;72(5):761-768. doi: 10.1002/art.41179van Vollenhoven RF, Kalunian KC, Dörner T, et alPhase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. Published Online First: 07 July 2022. doi: 10.1136/ard-2022-222858van Vollenhoven RF, Kalunian KC, Dörner T, et alPhase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. Published Online First: 07 July 2022. doi: 10.1136/ard-2022-222858US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT04181762.US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT04181762.US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT04376827.US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT04376827.Boedigheimer MJ, Martin DA, Amoura Z, Sánchez-Guerrero J, Romero-Diaz J, Kivitz A, et al. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci Med. 2017;4(1):e000226. doi: 10.1136/lupus-2017-000226Boedigheimer MJ, Martin DA, Amoura Z, Sánchez-Guerrero J, Romero-Diaz J, Kivitz A, et al. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci Med. 2017;4(1):e000226. doi: 10.1136/lupus-2017-000226Werth VP, Fiorentino D, Sullivan BA, Boedigheimer MJ, Chiu K, Wang C, et al. Brief report: Pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-γ antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. 2017;69(5):1028-1034. doi: 10.1002/art.40052Werth VP, Fiorentino D, Sullivan BA, Boedigheimer MJ, Chiu K, Wang C, et al. Brief report: Pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-γ antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol. 2017;69(5):1028-1034. doi: 10.1002/art.40052US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT02847598US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT02847598US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT04895241.US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT04895241.Werth V, Furie R, Romero-Díaz J, Navarra S, Kalunian K, van Vollenhoven R, et al. BIIB059. A humanized monoclonal antibody targeting blood dendritic cell antigen 2 on plasmacytoid dendritic cells, shows dose-related efficacy in a phase 2 study in participants with active cutaneous lupus erythematosus. Arthritis Rheumatol. 2020;72(Suppl 10). URL: https://acrabstracts.org/abstract/biib059-a-humanized-monoclonal-antibody-targetingblood-dendritic-cell-antigen-2-on-plasmacytoid-dendritic-cellsshows-dose-related-efficacy-in-a-phase-2-study-in-participantswith-active-cutaneous (Accessed: 11th July 2022).Werth V, Furie R, Romero-Díaz J, Navarra S, Kalunian K, van Vollenhoven R, et al. BIIB059. A humanized monoclonal antibody targeting blood dendritic cell antigen 2 on plasmacytoid dendritic cells, shows dose-related efficacy in a phase 2 study in participants with active cutaneous lupus erythematosus. Arthritis Rheumatol. 2020;72(Suppl 10). URL: https://acrabstracts.org/abstract/biib059-a-humanized-monoclonal-antibody-targetingblood-dendritic-cell-antigen-2-on-plasmacytoid-dendritic-cellsshows-dose-related-efficacy-in-a-phase-2-study-in-participantswith-active-cutaneous (Accessed: 11th July 2022).Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019; 129(3):1359-1371. doi: 10.1172/JCI124466Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019; 129(3):1359-1371. doi: 10.1172/JCI124466Zhang H, Liu Z, Huang L, Hou J, Zhou M, Huang X, et al. The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Lupus. 2017;26(9):952-958. doi: 10.1177/0961203316686703Zhang H, Liu Z, Huang L, Hou J, Zhou M, Huang X, et al. The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Lupus. 2017;26(9):952-958. doi: 10.1177/0961203316686703Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, et al. Efficacy and safety of bortezomib in refractory lupus nephritis: A single-center experience. Lupus. 2020;29(2): 118-125. doi: 10.1177/0961203319896018Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, et al. Efficacy and safety of bortezomib in refractory lupus nephritis: A single-center experience. Lupus. 2020;29(2): 118-125. doi: 10.1177/0961203319896018Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149-1155. doi: 10.1056/NEJMoa2023325Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149-1155. doi: 10.1056/NEJMoa2023325Hasni S, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Joyal E, et al. Safety and tolerability of omalizumab: A randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(7): 1135-1140. doi: 10.1002/art.40828Hasni S, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Joyal E, et al. Safety and tolerability of omalizumab: A randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(7): 1135-1140. doi: 10.1002/art.40828US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT03843125.US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT03843125.US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT03616964.US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT03616964.US National library of Medicine. ClinicalTrials.gov. URL https://ClinicalTrials.gov/show/NCT03616912.US National library of Medicine. ClinicalTrials.gov. URL https://ClinicalTrials.gov/show/NCT03616912.Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-231. doi: 10.1016/S0140-6736(18) 31363-1Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-231. doi: 10.1016/S0140-6736(18) 31363-1Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. doi: 10.1038/s41467-021- 23361-zHasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. doi: 10.1038/s41467-021- 23361-zMorand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. LB0004 Efficacy and safety of deucravacitinib, an oral, selective, allosteric Tyk2 inhibitor, in patients with active systemic lupus erythematosus: A phase 2, Randomized, DoubleBlind, Placebo-Controlled Study. Ann Rheum Dis. 2022;81:209. doi: 10.1136/annrheumdis-2022-eular.5020aMorand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. LB0004 Efficacy and safety of deucravacitinib, an oral, selective, allosteric Tyk2 inhibitor, in patients with active systemic lupus erythematosus: A phase 2, Randomized, DoubleBlind, Placebo-Controlled Study. Ann Rheum Dis. 2022;81:209. doi: 10.1136/annrheumdis-2022-eular.5020aIsenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: Results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021; 73(10):1835-1846. doi: 10.1002/art.41811Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: Results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021; 73(10):1835-1846. doi: 10.1002/art.41811US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT03021499.US National library of Medicine. ClinicalTrials.gov. URL: https://ClinicalTrials.gov/show/NCT03021499.Furie RA, Hough DR, Gaudy A, Ye Y, Korish S, Delev N, et al. Iberdomide in patients with systemic lupus erythematosus: A randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. 2022;9(1):e000581. doi: 10.1136/lupus-2021-000581Furie RA, Hough DR, Gaudy A, Ye Y, Korish S, Delev N, et al. Iberdomide in patients with systemic lupus erythematosus: A randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. 2022;9(1):e000581. doi: 10.1136/lupus-2021-000581Burge DJ, Eisenman J, Byrnes-Blake K, Smolak P, Lau K, Cohen SB, et al. Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled study. Lupus. 2017;26(8):825-834. doi: 10.1177/0961203316678675Burge DJ, Eisenman J, Byrnes-Blake K, Smolak P, Lau K, Cohen SB, et al. Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled study. Lupus. 2017;26(8):825-834. doi: 10.1177/0961203316678675Burge D, Doedens J, Eisenman J, Elkon K, Gabel C, Posada J. THU0293 Safety, pharmacokinetics, enzyme activity, and immunogenicity of RSLV-132, a novel RNAse fusion protein developed to reduce RNA-containing immune complexes in systemic lupus erythematosus. Ann Rheum Dis. 2016;75:292-293. doi: 10.1136/ annrheumdis-2016-eular.2744Burge D, Doedens J, Eisenman J, Elkon K, Gabel C, Posada J. THU0293 Safety, pharmacokinetics, enzyme activity, and immunogenicity of RSLV-132, a novel RNAse fusion protein developed to reduce RNA-containing immune complexes in systemic lupus erythematosus. Ann Rheum Dis. 2016;75:292-293. doi: 10.1136/ annrheumdis-2016-eular.2744Szelinski F, Lino AC, Dörner T. B cells in systemic lupus erythematosus. Curr Opin Rheumatol. 2022;34(2):125-132. doi: 10.1097/BOR.0000000000000865Szelinski F, Lino AC, Dörner T. B cells in systemic lupus erythematosus. Curr Opin Rheumatol. 2022;34(2):125-132. doi: 10.1097/BOR.0000000000000865Piantoni S, Korsten P. Rituximab-a B cell targeted therapy in systemic lupus erythematosus: Where do we stand? Rheumatology (Oxford). 2022;61(5):1752-1755. doi: 10.1093/rheumatology/keac095Piantoni S, Korsten P. Rituximab-a B cell targeted therapy in systemic lupus erythematosus: Where do we stand? Rheumatology (Oxford). 2022;61(5):1752-1755. doi: 10.1093/rheumatology/keac095Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi: 10.1038/s41573-020- 00092-2Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi: 10.1038/s41573-020- 00092-2Atisha-Fregoso Y, Toz B, Diamond B. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Invest. 2021;131(12):e149095. doi: 10.1172/JCI149095Atisha-Fregoso Y, Toz B, Diamond B. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Invest. 2021;131(12):e149095. doi: 10.1172/JCI149095Fernández González R, Abida R, Gisca E, Duarte L, Isenberg DA. Can we predict if patients with SLE will require more than one cycle of rituximab? Rheumatology (Oxford). 2022;61(5):1892-1899. doi: 10.1093/rheumatology/keab527Fernández González R, Abida R, Gisca E, Duarte L, Isenberg DA. Can we predict if patients with SLE will require more than one cycle of rituximab? Rheumatology (Oxford). 2022;61(5):1892-1899. doi: 10.1093/rheumatology/keab527Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-1509. doi: 10.2215/CJN.01070118Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-1509. doi: 10.2215/CJN.01070118Marinov AD, Wang H, Bastacky SI, van Puijenbroek E, Schindler T, Speziale D, et al. The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model. Arthritis Rheumatol. 2021;73(5):826-836. doi: 10.1002/art.41608Marinov AD, Wang H, Bastacky SI, van Puijenbroek E, Schindler T, Speziale D, et al. The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model. Arthritis Rheumatol. 2021;73(5):826-836. doi: 10.1002/art.41608Stohl W, Hilbert DM. The discovery and development of belimumab: The anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69-77. doi: 10.1038/nbt.2076Stohl W, Hilbert DM. The discovery and development of belimumab: The anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69-77. doi: 10.1038/nbt.2076Насонов ЕЛ, Решетняк ТМ, Денисов ЛН, Соловьев СК. Белимумаб: прогресс в лечении системной красной волчанки. Научно-практическая ревматология. 2012;50(5):13-19. doi: 10.14412/1995-4484-2012-1174Nasonov EL, Reshetnyak TM, Denisov LN, Stanislav ML, Solovyov SK. Belimumab: Advances in drug therapy for systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2012;50(5):13-19 (In Russ.). doi: 10.14412/1995-4484-2012-1174Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi: 10.47360/1995-4484-2021-367-383Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.). doi: 10.47360/1995-4484-2021-367-383Smulski CR, Eibel H. BAFF and BAFF-Receptor in B cell selection and survival. Front Immunol. 2018;9:2285. doi: 10.3389/fimmu.2018.02285Smulski CR, Eibel H. BAFF and BAFF-Receptor in B cell selection and survival. Front Immunol. 2018;9:2285. doi: 10.3389/fimmu.2018.02285Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/ APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-373. doi: 10.1038/nrrheum.2014.33Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/ APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-373. doi: 10.1038/nrrheum.2014.33Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2(2):CD010668. doi: 10.1002/14651858.CD010668.pub2Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2(2):CD010668. doi: 10.1002/14651858.CD010668.pub2Poh YJ, Baptista B, D’Cruz DP. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: A review of data on subcutaneous and intravenous administration. Expert Rev Clin Immunol. 2017;13(10):925-938. doi: 10.1080/1744 666X.2017.1371592Poh YJ, Baptista B, D’Cruz DP. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: A review of data on subcutaneous and intravenous administration. Expert Rev Clin Immunol. 2017;13(10):925-938. doi: 10.1080/1744 666X.2017.1371592Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents. Front Med (Lausanne). 2020;7:303. doi: 10.3389/fmed.2020.00303Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents. Front Med (Lausanne). 2020;7:303. doi: 10.3389/fmed.2020.00303Bela MM, Espinosa G, Cervera R. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. Lupus. 2021;30(1):134-140. doi: 10.1177/0961203320965707Bela MM, Espinosa G, Cervera R. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. Lupus. 2021;30(1):134-140. doi: 10.1177/0961203320965707Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, et al.; BEAT-LUPUS Investigators. Effectiveness of belimumab after rituximab in systemic lupus erythematosus: A randomized controlled trial. Ann Intern Med. 2021;174(12):1647- 1657. doi: 10.7326/M21-2078Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, et al.; BEAT-LUPUS Investigators. Effectiveness of belimumab after rituximab in systemic lupus erythematosus: A randomized controlled trial. Ann Intern Med. 2021;174(12):1647- 1657. doi: 10.7326/M21-2078Aranow C, Allaart C, Amoura Z, Bruce I, Cagnoli P, Furie R, et al. Efficacy and safety of subcutaneous belimumab (BEL) and rituximab (RTX) sequential therapy in patients with systemic lupus erythematosus: The phase 3, randomized, placebo-controlled BLISS-BELIEVE Study. Arthritis Rheumatol. 2021;73(Suppl 10).Aranow C, Allaart C, Amoura Z, Bruce I, Cagnoli P, Furie R, et al. Efficacy and safety of subcutaneous belimumab (BEL) and rituximab (RTX) sequential therapy in patients with systemic lupus erythematosus: The phase 3, randomized, placebo-controlled BLISS-BELIEVE Study. Arthritis Rheumatol. 2021;73(Suppl 10).Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7(3):170-178. doi: 10.1038/nrrheum.2011.1Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7(3):170-178. doi: 10.1038/nrrheum.2011.1Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219. doi: 10.1056/NEJMoa1506348Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219. doi: 10.1056/NEJMoa1506348Orvain C, Boulch M, Bousso P, Allanore Y, Avouac J. Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol. 2021;73(11):1954-1965. doi: 10.1002/art.41812Orvain C, Boulch M, Bousso P, Allanore Y, Avouac J. Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol. 2021;73(11):1954-1965. doi: 10.1002/art.41812Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019;11(482):eaav1648. doi: 10.1126/scitranslmed. aav1648Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019;11(482):eaav1648. doi: 10.1126/scitranslmed. aav1648Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2021;18(8):1896-1903. doi: 10.1038/s41423-020-0472-1Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2021;18(8):1896-1903. doi: 10.1038/s41423-020-0472-1Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567-569. doi: 10.1056/NEJMc2107725Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567-569. doi: 10.1056/NEJMc2107725Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol. 2019;14:369-393. doi: 10.1146/ annurev-pathol-020117-043952Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol. 2019;14:369-393. doi: 10.1146/ annurev-pathol-020117-043952Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019; 57(4):452-461. doi: 10.14412/1995-4484-2019-452-461Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):452-461 (In Russ.). doi: 10.14412/1995-4484-2019-452-461Rönnblom L, Leonard D. Interferon pathway in SLE: One key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270. doi: 10.1136/lupus-2018-000270Rönnblom L, Leonard D. Interferon pathway in SLE: One key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270. doi: 10.1136/lupus-2018-000270Paredes JL, Niewold TB. Type I interferon antagonists in clinical development for lupus. Expert Opin Investig Drugs. 2020;29(9):1025-1041. doi: 10.1080/13543784.2020.1797677Paredes JL, Niewold TB. Type I interferon antagonists in clinical development for lupus. Expert Opin Investig Drugs. 2020;29(9):1025-1041. doi: 10.1080/13543784.2020.1797677Chaichian Y, Strand V. Interferon-directed therapies for the treatment of systemic lupus erythematosus: A critical update. Clin Rheumatol. 2021;40(8):3027-3037. doi: 10.1007/s10067-020-05526-1Chaichian Y, Strand V. Interferon-directed therapies for the treatment of systemic lupus erythematosus: A critical update. Clin Rheumatol. 2021;40(8):3027-3037. doi: 10.1007/s10067-020-05526-1Goulden B, Isenberg D. Anti-IFNαR MAbs for the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021; 21(4):519-528. doi: 10.1080/14712598.2021.1841164Goulden B, Isenberg D. Anti-IFNαR MAbs for the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021; 21(4):519-528. doi: 10.1080/14712598.2021.1841164Peng L, Oganesyan V, Wu H, Dall’Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti- interferon-α receptor 1 antibody. MAbs. 2015;7(2):428-439. doi: 10.1080/19420862.2015.1007810Peng L, Oganesyan V, Wu H, Dall’Acqua WF, Damschroder MM. Molecular basis for antagonistic activity of anifrolumab, an anti- interferon-α receptor 1 antibody. MAbs. 2015;7(2):428-439. doi: 10.1080/19420862.2015.1007810Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi: 10.1136/lupus-2018-000261Riggs JM, Hanna RN, Rajan B, Zerrouki K, Karnell JL, Sagar D, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi: 10.1136/lupus-2018-000261Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. doi: 10.1093/rheumatology/kew431Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. doi: 10.1093/rheumatology/kew431Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12): 843-862. doi: 10.1038/nrd.2017.201Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12): 843-862. doi: 10.1038/nrd.2017.201Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: New opportunities and prospects Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.). doi: 10.14412/1995-4484-2019-8-16Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133-145. doi:10.1038/s41584-021-00726-8Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133-145. doi:10.1038/s41584-021-00726-8Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-3052. doi: 10.1172/JCI98814Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-3052. doi: 10.1172/JCI98814König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-472. doi: 10.1136/annrheumdis-2016-209841König N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tüngler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-472. doi: 10.1136/annrheumdis-2016-209841Rodero MP, Frémond ML, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75. doi: 10.1136/annrheumdis-2016-210504Rodero MP, Frémond ML, Rice GI, Neven B, Crow YJ. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75. doi: 10.1136/annrheumdis-2016-210504You H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: The experience from a single centre. Ann Rheum Dis. 2019;78(10):1441-1443. doi: 10.1136/annrheumdis-2019-215455You H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: The experience from a single centre. Ann Rheum Dis. 2019;78(10):1441-1443. doi: 10.1136/annrheumdis-2019-215455Bisoendial R, Lubberts E. A mechanistic insight into the pathogenic role of interleukin 17A in systemic autoimmune diseases. Mediators Inflamm. 2022;2022:6600264. doi: 10.1155/2022/6600264Bisoendial R, Lubberts E. A mechanistic insight into the pathogenic role of interleukin 17A in systemic autoimmune diseases. Mediators Inflamm. 2022;2022:6600264. doi: 10.1155/2022/6600264Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283-294. doi: 10.1038/nri3823Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283-294. doi: 10.1038/nri3823He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991-993. doi: 10.1038/nm.4148He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991-993. doi: 10.1038/nm.4148von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75(7):1407-1415. doi: 10.1136/annrheumdis-2015-207776von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75(7):1407-1415. doi: 10.1136/annrheumdis-2015-207776Humrich JY, von Spee-Mayer C, Siegert E Bertolo M, Rose A, Abdirama D, et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: An investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol. 2019;1:e44-e54.Humrich JY, von Spee-Mayer C, Siegert E Bertolo M, Rose A, Abdirama D, et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: An investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol. 2019;1:e44-e54.Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141-149. doi: 10.1136/ annrheumdis-2019-215396He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141-149. doi: 10.1136/ annrheumdis-2019-215396Huang X, Chen W, Ren G, Zhao L, Guo J, Gong D, et al. Autologous hematopoietic stem cell transplantation for refractory lupus nephritis. Clin J Am Soc Nephrol. 2019;14(5):719-727. doi: 10.2215/CJN.10570918 184. Li W, Chen W, Sun L. An update for mesenchymal stem cell therapy in lupus nephritis. Kidney Dis (Basel). 2021;7(2):79-89. doi: 10.1159/000513741Huang X, Chen W, Ren G, Zhao L, Guo J, Gong D, et al. Autologous hematopoietic stem cell transplantation for refractory lupus nephritis. Clin J Am Soc Nephrol. 2019;14(5):719-727. doi: 10.2215/CJN.10570918 184. Li W, Chen W, Sun L. An update for mesenchymal stem cell therapy in lupus nephritis. Kidney Dis (Basel). 2021;7(2):79-89. doi: 10.1159/000513741Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113(1):214-223. doi: 10.1182/blood-2008-07-168286Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113(1):214-223. doi: 10.1182/blood-2008-07-168286Leng XM, Jiang Y, Zhou DB, Tian XP, Li TS, Wang SJ, et al. Good outcome of severe lupus patients with high-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation: A 10-year follow-up study. Clin Exp Rheumatol. 2017;35(3):494-499.Leng XM, Jiang Y, Zhou DB, Tian XP, Li TS, Wang SJ, et al. Good outcome of severe lupus patients with high-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation: A 10-year follow-up study. Clin Exp Rheumatol. 2017;35(3):494-499.Cao C, Wang M, Sun J, Peng X, Liu Q, Huang L, et al. Autologous peripheral blood haematopoietic stem cell transplantation for systemic lupus erythematosus: the observation of long-term outcomes in a Chinese centre. Clin Exp Rheumatol. 2017;35(3):500-507.Cao C, Wang M, Sun J, Peng X, Liu Q, Huang L, et al. Autologous peripheral blood haematopoietic stem cell transplantation for systemic lupus erythematosus: the observation of long-term outcomes in a Chinese centre. Clin Exp Rheumatol. 2017;35(3):500-507.de Silva NL, Seneviratne SL. Haemopoietic stem cell transplantation in Systemic lupus erythematosus: А systematic review. Allergy Asthma Clin Immunol. 2019;15:59. doi: 10.1186/ s13223-019-0373-yde Silva NL, Seneviratne SL. Haemopoietic stem cell transplantation in Systemic lupus erythematosus: А systematic review. Allergy Asthma Clin Immunol. 2019;15:59. doi: 10.1186/ s13223-019-0373-yDing DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011;20(1):5-14. doi: 10.3727/096368910XDing DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011;20(1):5-14. doi: 10.3727/096368910XLi J, Luo M, Li B, Lou Y, Zhu Y, Bai X, et al. Immunomodulatory activity of mesenchymal stem cells in lupus nephritis: Advances and applications. Front Immunol. 2022;13:843192. doi: 10.3389/ fimmu.2022.843192Li J, Luo M, Li B, Lou Y, Zhu Y, Bai X, et al. Immunomodulatory activity of mesenchymal stem cells in lupus nephritis: Advances and applications. Front Immunol. 2022;13:843192. doi: 10.3389/ fimmu.2022.843192Zeng L, Yu G, Yang K, Xiang W, Li J, Chen H. Efficacy and safety of mesenchymal stem cell transplantation in the treatment of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, and ankylosing spondylitis): A systematic review and meta-analysis of randomized controlled trial. Stem Cells Int. 2022;2022:9463314. doi: 10.1155/2022/9463314Zeng L, Yu G, Yang K, Xiang W, Li J, Chen H. Efficacy and safety of mesenchymal stem cell transplantation in the treatment of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, and ankylosing spondylitis): A systematic review and meta-analysis of randomized controlled trial. Stem Cells Int. 2022;2022:9463314. doi: 10.1155/2022/9463314Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436-1439. doi: 10.1136/annrheumdis-2017-211073Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436-1439. doi: 10.1136/annrheumdis-2017-211073Weinstein A, Alexander RV, Zack DJ. A review of complement activation in SLE. Curr Rheumatol Rep. 2021;23(3):16. doi: 10.1007/s11926-021-00984-1Weinstein A, Alexander RV, Zack DJ. A review of complement activation in SLE. Curr Rheumatol Rep. 2021;23(3):16. doi: 10.1007/s11926-021-00984-1Насонов ЕЛ, Решетняк ТМ, Алекберова ЗС. Тромботическая микроангиопатия в ревматологии: связь тромбовоспаления и аутоиммунитета. Терапевтический архив. 2020;92(5). doi: 10.26442/00403660.2020.05.000697Nasonov EL, Reshetnyak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: A link between thrombosis and autoimmunity. Terapevticheskii arkhiv. 2020;92(5) (In Russ.). doi: 10.26442/00403660.2020.05.000697Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosusassociated thrombotic microangiopathy. BMC Nephrol. 2020;21(1):245. doi: 10.1186/s12882-020-01888-5Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosusassociated thrombotic microangiopathy. BMC Nephrol. 2020;21(1):245. doi: 10.1186/s12882-020-01888-5Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford). 2015;54(12):2286- 2288. doi: 10.1093/rheumatology/kev307Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford). 2015;54(12):2286- 2288. doi: 10.1093/rheumatology/kev307Spihlman AP, Gadi N, Wu SC, Moulton VR. COVID-19 and systemic lupus erythematosus: Focus on immune response and therapeutics. Front Immunol. 2020;11:589474. doi: 10.3389/fimmu.2020.589474Spihlman AP, Gadi N, Wu SC, Moulton VR. COVID-19 and systemic lupus erythematosus: Focus on immune response and therapeutics. Front Immunol. 2020;11:589474. doi: 10.3389/fimmu.2020.589474Насонов ЕЛ, Авдеева АС. Деплеция В-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (COVID-19). Научно-практическая ревматология. 2021;59(4):384-393. doi: 10.47360/1995-4484- 2021-384-393Nasonov EL, Avdeeva AS. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):384-393 (In Russ.). doi: 10.47360/1995-4484- 2021-384-393Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021;59(1):5-30. doi: 10.47360/1995-4484-2021-5-30Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1): 5-30 (In Russ.). doi: 10.47360/1995-4484-2021-5-30Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi: 10.1038/s41598-021-95565-8Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi: 10.1038/s41598-021-95565-8Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):5417. doi: 10.1038/s41467-021-25509-3Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):5417. doi: 10.1038/s41467-021-25509-3Tamariz L, Bast E, Abad M, Klimas N, Caralis P, Palacio A. Post COVID-19 joint pain: Preliminary report of the relationship with antinuclear antibodies and inflammation. J Med Virol. 2022;94(8):3479-3481. doi: 10.1002/jmv.27753Tamariz L, Bast E, Abad M, Klimas N, Caralis P, Palacio A. Post COVID-19 joint pain: Preliminary report of the relationship with antinuclear antibodies and inflammation. J Med Virol. 2022;94(8):3479-3481. doi: 10.1002/jmv.27753Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, et al. 16th International Congress on Antiphospholipid Antibodies task force report on antiphospholipid syndrome treatment trends. Lupus. 2020;29(12):1571-1593. doi: 10.1177/0961203320950461Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, et al. 16th International Congress on Antiphospholipid Antibodies task force report on antiphospholipid syndrome treatment trends. Lupus. 2020;29(12):1571-1593. doi: 10.1177/0961203320950461Erkan D. Expert perspective: Management of microvascular and catastrophic antiphospholipid syndrome. Arthritis Rheumatol. 2021;73(10):1780-1790. doi: 10.1002/art.41891Erkan D. Expert perspective: Management of microvascular and catastrophic antiphospholipid syndrome. Arthritis Rheumatol. 2021;73(10):1780-1790. doi: 10.1002/art.41891Gao Y, Wang Y, Li R, Zhou X. Comprehensive analysis of clinical trials registration for lupus nephritis therapy on ClinicalTrials.gov. Front Med (Lausanne). 2021;8:680302. doi: 10.3389/fmed.2021. 680302Gao Y, Wang Y, Li R, Zhou X. Comprehensive analysis of clinical trials registration for lupus nephritis therapy on ClinicalTrials.gov. Front Med (Lausanne). 2021;8:680302. doi: 10.3389/fmed.2021. 680302

The authors declare that there are no conflicts of interest present.